Novartis and Xencor enter bispecific antibody collaboration
Novartis and Xencor are to develop bispecific antibodies for treating cancer.
The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.
Click on this link for more information.
